Abstract
Ionizing radiation inflicts lethal double-strand DNA breaks and oxidative stress that underlie acute radiation syndrome, secondary malignancies, and dose-limiting toxicity in radiotherapy; yet the conventional armamentarium of radioprotectants-aminothiols, broad-spectrum antioxidants, cytokines, and superoxide-dismutase mimetics-yields only modest benefit because of narrow therapeutic windows, systemic toxicity, and inadequate protection of radiosensitive tissues. In striking contrast, tardigrades (phylum Tardigrada) routinely endure exposures beyond 5 kGy by deploying a multifaceted defense repertoire that includes genome-shielding proteins such as damage suppressor (Dsup) and Tardigrade DNA-Repair protein 1 (TDR1), families of intrinsically disordered proteins that vitrify cytoplasm and scavenge radicals, antioxidant pigments acquired via horizontal gene transfer, and exceptionally efficient DNA-repair and redox networks. Viewing radioprotection through a translational pharmacology lens reveals a pipeline of emerging modalities-including recombinant or cell-penetrating proteins, mRNA therapeutics, peptidomimetics, and biomimetic nanomaterials-while also spotlighting critical hurdles of scalable bioprocessing, macromolecule stability, immunogenicity, and targeted delivery. By integrating insights from extremophile biology with cutting-edge drug-discovery platforms, tardigrade-inspired interventions promise to safeguard healthy tissue during cancer treatment, reduce casualties in nuclear accidents, and shield astronauts on deep-space missions, thereby redefining the future landscape of radioprotection and transforming an evolutionary curiosity into a potent arsenal of medical countermeasures.